From: Recent advances of m6A methylation in skeletal system disease
m6A regulators | Cells | Animals | Expression of m6A regulators | Pathway | Biological function | Reference |
---|---|---|---|---|---|---|
METTL3 | mouse bone marrow mononuclear macrophages | OVX mouse model | Up | EGR1/METTL3/ CHI3L1 | Promoted osteoclast differentiation and osteoporosis development | [121] |
BALB/c mice BMSC | – | Up | MHL/METTL3 | Enhanced osteoblastogenesis | [122] | |
adipose stem cells in OP rats | OVX mouse model | Down | – | Decreased osteogenic differentiation capacity | [123] | |
HUXMA -01 BMSCs | Female C57BL/6Â J mice | Up | METTL3/ MIR99AHG/ miR-4660 | enhanced the osteogenic differentiation | [124] | |
OP mouse BMSCs | OVX mouse model | Down | Wnt signaling pathway | Decreased osteogenic potential | [125] | |
Human OP BMSCs | – | Down | MRTTL3/ LINC00657/ miR-144-3p/ BMPR1B | Promoted osteogenic differentiation | [126] | |
MC3T3-E1 cells, Balb/c mouse BMSCs | Diabetic bone loss rat model | Up | METTL3/ ASK1-p38 | Activated osteoblast ferroptosis | [127] | |
Human BMSCs | OVX mouse model | Up | piRNA-36741/ METTL3/ BMP2 | Promoted osteogenic differentiation | [128] | |
Human BMSCs | OVX mouse model | Down | METTL3/ pre-miR-320/ RUNX2 | Inhibited osteogenic differentiation | [129] | |
Mouse BMSCs | OVX mouse model | Down | METTL3/ PTH /Pth1r | Impaired bone formation, osteogenic differentiation potential and increased marrow adiposity | [130] | |
METTL14 | Murine RAW264.7 and MC3T3-E1 cell lines | – | Up | METTL14/ NFATc1/ YTHDF1-2 | Decreased bone resorption of osteoclasts | [131] |
Human BMSCs | – | Up | METTL14 / miR-873 | Inhibited osteogenic proliferation and differentiation | [132] | |
Human BMSCs | OVX mouse model | Down | METTL14/ GPX4 | Promoted osteoclastogenesis and bone resorption | [133] | |
Mouse BMSCs | OVX mouse model | Down | METTL14/ SIRT1 | Suppressed osteoblast differentiation and promoted osteoclast differentiation | [134] | |
Human BMSCs | OVX mouse model | Down | METTL14/TCF1/ RUNX2 | Suppressed osteoblast differentiation and promoted osteoclast differentiation | [135] | |
Human BMSCs | OVX mouse model | Down | METTL14/ SMAD1/IGFBP1 | Inhibited osteogenic differentiation | [136] | |
Human BMSCs | OVX mouse model | Down | METTL14/ IGF2BPs/Beclin-1 | Inhibited osteogenic differentiation and promoted osteoclast differentiation | [137] | |
Mouse ASCs | OVX mouse model | Down | METTL14/ Notch1 | Inhibited osteogenic differentiation | [138] | |
Human BMSCs | OVX mouse model | Down | miR-103-3p/ METTL14 | Inhibited osteoblast proliferation, differentiation, and matrix mineralization | [139] | |
WTAP | Human BMSCs | OVX mouse model | Down | WTAP/DGCR8 miR-29b-3p/ HDAC4 | Inhibited osteogenic differentiation and promoted adipogenic differentiation | [140] |
Human BMSCs | OVX mouse model | Down | WTAP/YTHDC1/miR-181a and miR-181c/SFRP1 | Inhibited osteogenic differentiation and promoted adipogenic differentiation | [141] | |
FTO | Mouse RAW264.7 cells | diabetic mouse model | Down | FTO/ TLR4 | Promoted osteoclast differentiation | [120] |
 | Human BMSCs | – | Down | FTO/YTHDF1/ PPARG | Inhibited osteogenic differentiation | [142] |
 | – | OVX mouse model | UP | FTO/ NF-κB/ NFATc1 | Promoted bone resorption and osteoclastogenesis | [143] |
 | Human BMSCs | OVX mouse model | Up | FTO/Runx2 | Promotes osteoporosis, inhibited osteogenic differentiation | [144] |
 | Human BMSCs | OVX mouse model | Up | miR-22-3p/ FTO/MYC/PI3K/AKT | Promotes osteoporosis, inhibited osteogenic differentiation | [145] |
 | Mouse BMSCs | – | Down | miR-149-3p/FTO | Inhibited the adipogenic differentiation | [146] |
ALKBH1 | Mouse BMSCs | Alkbh1 knockout mice model | Down | ALKBH1/ optn | Reduced bone mass and increased marrow adiposity | [147] |